SCHEMBL12457437

SCHEMBL12457437

Cc1ccccc1-c1nnn(C)c1C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.38
▸ TDO2 P48775 1/20 0.38
▸ JAK2 O60674 1/20 0.38
▸ JAK1 P23458 1/20 0.38
▸ TYK2 P29597 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ CASP3 P42574 1/20 0.38
▸ SENP8 Q96LD8 1/20 0.38
▸ SENP7 Q9BQF6 1/20 0.38
▸ SENP6 Q9GZR1 1/20 0.38
▸ DCTPP1 Q9H773 2/20 0.38
▸ ALDH1A1 P00352 5/20 0.37
▸ LMNA P02545 3/20 0.37
▸ HPGD P15428 3/20 0.37
▸ PKM P14618 2/20 0.37
▸ TDP2 O95551 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12457436 0.77 RECQL (0.41) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL12691921 0.73 DPP4 (0.40) JAK2JAK1TYK2JAK3NPC1
SCHEMBL5275970 0.69 SLC9A1 (0.32) SLC9A1KEAP1
SCHEMBL23400556 0.68 LDHA (0.37) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL5968451 0.67 NPC1 (0.41) IDO1TDO2JAK2JAK1TYK2
SCHEMBL22786993 0.66 KCNN4 (0.47) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL14551995 0.65 SLC9A1 (0.47) IDO1TDO2SMN1; SMN2HPGDHTT
SCHEMBL14551997 0.65 SLC9A1 (0.47) IDO1TDO2SMN1; SMN2HPGDHTT
SCHEMBL13846109 0.65 PDK2 (0.48) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL21366127 0.62 TOP2A (0.36) IDO1TDO2JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362004-B2 Piperazine analogs as broad-spectrum influenza antivirals BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 — — US disclosed
US-20120245176-A1 NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS BRISTOL-MYERS SQUIBB COMPANY 2012-09-27 — — US disclosed
US-20120238539-A1 NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS BRISTOL-MYERS SQUIBB COMPANY 2012-09-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238539-A1 NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS ZC3HAV1, ZC3HAV1L, HCRTR1 IDO1 17/4885TDO2 1217/4885JAK2 895/4885
US-20120245176-A1 NOVEL PIPERAZINE ANALOGS WITH SUBSTITUTED HETEROARYL GROUPS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS ZC3HAV1, ZC3HAV1L, BAZ2A IDO1 214/4885TDO2 1426/4885JAK2 742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback